Issuers will hope the outperformance continues, as consensus is now that there will be no EPS growth in Q1. Bank of America ...

Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.

A federal appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic version of its blockbuster heart failure drug Entresto. The US Court of Appeals ...